Ph. D., Management of Technology, Sungkyunkwan University ;
M.P.H., Health Policy & Economics, School of Public Health, Seoul National University ;
B.Pharm., College of Pharmacy, Seoul National University ;
Experience
Assistant Professor, School of Pharmacy, Sungkyunkwan University, 2018 ~ present ;
Industry Cooperation Professor, School of Pharmacy, Sungkyunkwan University, 2016 ~ 2018 ;
Director, Korea Health Industry Development Institute (KHIDI), 2013 ~ 2016 ;
Senior Researcher, Korea Health Industry Development Institute (KHIDI), 1999 ~ 2013 ;
Visiting Scholar, The Wharton School, University of Pennsylvania, 2003 ;
Journal Articles
(2023)
Does Firm’s alliances Increase New Drug Development Time? A Multiple Regression Analysis of Clinical Development Time.
JOURNAL OF PHARMACEUTICAL INNOVATION.
(2022)
Impact of Collaboration on Clinical Development Time.
Yakhak Hoeji.
66,
6
(2022)
Understanding patient and physician responses to various cost-sharing programs for prescription drugs in South Korea: A multilevel analysis.
FRONTIERS IN PUBLIC HEALTH.
10,
-
(2022)
Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in South Korea: a nationwide cross-sectional survey.
EPIDEMIOLOGY AND HEALTH.
44,
e2022061
(2022)
Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors.
CANCER RESEARCH AND TREATMENT.
54,
1
(2021)
Effects of Marketing-Sales-Interface Capability on Sales Performance for Medical Representative in Pharmaceutical Company.
The Journal of the Korea Contents Association.
21,
11
(2021)
Digital therapeutics and the future.
Journal of Korean Society of Health-System Pharmacists.
38,
3
(2021)
Innovation Characteristics of COVID-19 Vaccine Development and Its Implications.
Korean journal of bioeconomy.
4,
1
(2020)
Relationship Between Research and Development Investment and Firm-specific Factors of Korean Pharmaceutical Firms: A Nonparametric Approach.
The Korean Journal of Health Service Management.
14,
3
(2020)
Analysis of Development Time of New Drugs Developed by Korean Domestic Companies.
Yakhak Hoeji.
64,
4
(2020)
Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE.
54,
2
(2018)
Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES.
21,
6
(2018)
조건부가치평가법(CVM)을 이용한 한-EFTA간 제약 산업 상호인정협약 체결의 경제적 효과 분석.
한국산학기술학회논문지.
19,
5
